These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 36130840)

  • 41. Amyloid and tau positive mild cognitive impairment: clinical and biomarker characteristics of dementia progression.
    Wei HC; Li B; Ng KP; Fu QX; Dong SJ; Ba MW; Kong M
    Chin Med J (Engl); 2021 Jul; 134(14):1709-1719. PubMed ID: 34397597
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany.
    Bartels C; Kögel A; Schweda M; Wiltfang J; Pentzek M; Schicktanz S; Schneider A
    J Alzheimers Dis; 2020; 78(3):1137-1148. PubMed ID: 33104034
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CSF peptides from VGF and other markers enhance prediction of MCI to AD progression using the ATN framework.
    Llano DA; Devanarayan P; Devanarayan V;
    Neurobiol Aging; 2023 Jan; 121():15-27. PubMed ID: 36368195
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The recency ratio is related to CSF amyloid beta 1-42 levels in MCI-AD.
    Bruno D; Gleason CE; Koscik RL; Pomara N; Zetterberg H; Blennow K; Johnson SC
    Int J Geriatr Psychiatry; 2019 Mar; 34(3):415-419. PubMed ID: 30430632
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prediction of Cognitive Progression in Individuals with Mild Cognitive Impairment Using Radiomics as an Improvement of the ATN System: A Five-Year Follow-Up Study.
    Song R; Wu X; Liu H; Guo D; Tang L; Zhang W; Feng J; Li C
    Korean J Radiol; 2022 Jan; 23(1):89-100. PubMed ID: 34983097
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.
    Jack CR; Wiste HJ; Weigand SD; Therneau TM; Knopman DS; Lowe V; Vemuri P; Mielke MM; Roberts RO; Machulda MM; Senjem ML; Gunter JL; Rocca WA; Petersen RC
    Lancet Neurol; 2017 Jun; 16(6):435-444. PubMed ID: 28456479
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CSF p-tau/Aβ
    Santangelo R; Masserini F; Agosta F; Sala A; Caminiti SP; Cecchetti G; Caso F; Martinelli V; Pinto P; Passerini G; Perani D; Magnani G; Filippi M
    Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3152-3164. PubMed ID: 32415550
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
    Mazzeo S; Santangelo R; Bernasconi MP; Cecchetti G; Fiorino A; Pinto P; Passerini G; Falautano M; Comi G; Magnani G
    J Alzheimers Dis; 2016 Oct; 54(4):1495-1508. PubMed ID: 27589522
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CSF cutoffs for MCI due to AD depend on APOEε4 carrier status.
    Marizzoni M; Ferrari C; Babiloni C; Albani D; Barkhof F; Cavaliere L; Didic M; Forloni G; Fusco F; Galluzzi S; Hensch T; Jovicich J; Marra C; Molinuevo JL; Nobili F; Parnetti L; Payoux P; Ranjeva JP; Ribaldi F; Rolandi E; Rossini PM; Salvatore M; Soricelli A; Tsolaki M; Visser PJ; Wiltfang J; Richardson JC; Bordet R; Blin O; Frisoni GB
    Neurobiol Aging; 2020 May; 89():55-62. PubMed ID: 32029236
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Amyloid, Tau, and Neurodegeneration (A/T/N) Classification Applied to a Clinical Research Cohort with Long-Term Follow-Up.
    Grøntvedt GR; Lauridsen C; Berge G; White LR; Salvesen Ø; Bråthen G; Sando SB
    J Alzheimers Dis; 2020; 74(3):829-837. PubMed ID: 32116257
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.
    Wolfsgruber S; Polcher A; Koppara A; Kleineidam L; Frölich L; Peters O; Hüll M; Rüther E; Wiltfang J; Maier W; Kornhuber J; Lewczuk P; Jessen F; Wagner M
    J Alzheimers Dis; 2017; 58(3):939-950. PubMed ID: 28527210
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cerebrospinal fluid profiles and prospective course and outcome in patients with amnestic mild cognitive impairment.
    Okonkwo OC; Mielke MM; Griffith HR; Moghekar AR; O'Brien RJ; Shaw LM; Trojanowski JQ; Albert MS;
    Arch Neurol; 2011 Jan; 68(1):113-9. PubMed ID: 21220682
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Usefulness of CSF Biomarkers in Predicting the Progression of Amnesic and Nonamnesic Mild Cognitive Impairment to Alzheimer's Disease.
    Ortega RL; Dakterzada F; Arias A; Blasco E; Naudí A; Garcia FP; Piñol-Ripoll G
    Curr Aging Sci; 2019; 12(1):35-42. PubMed ID: 31589110
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Potential eligibility for Aducanumab therapy in an Irish specialist cognitive service-Utilising cerebrospinal fluid biomarkers and appropriate use criteria.
    Togher Z; Dolphin H; Russell C; Ryan M; Kennelly SP; O'Dowd S
    Int J Geriatr Psychiatry; 2022 Aug; 37(8):. PubMed ID: 35861223
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Unbiased estimates of cerebrospinal fluid β-amyloid 1-42 cutoffs in a large memory clinic population.
    Bertens D; Tijms BM; Scheltens P; Teunissen CE; Visser PJ
    Alzheimers Res Ther; 2017 Feb; 9(1):8. PubMed ID: 28193256
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.
    Andreasen N; Minthon L; Davidsson P; Vanmechelen E; Vanderstichele H; Winblad B; Blennow K
    Arch Neurol; 2001 Mar; 58(3):373-9. PubMed ID: 11255440
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Glial activation and inflammation along the Alzheimer's disease continuum.
    Nordengen K; Kirsebom BE; Henjum K; Selnes P; Gísladóttir B; Wettergreen M; Torsetnes SB; Grøntvedt GR; Waterloo KK; Aarsland D; Nilsson LNG; Fladby T
    J Neuroinflammation; 2019 Feb; 16(1):46. PubMed ID: 30791945
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Real-word application of the AT(N) classification and disease-modifying treatment eligibility in a hospital-based cohort.
    Canu E; Rugarli G; Coraglia F; Basaia S; Cecchetti G; Calloni SF; Vezzulli PQ; Spinelli EG; Santangelo R; Caso F; Falini A; Magnani G; Filippi M; Agosta F
    J Neurol; 2024 May; 271(5):2716-2729. PubMed ID: 38381175
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.